Crestchem Ltd (526269)

Crestchem Ltd has submitted copies of newspaper advertisements concerning its unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The notices were published on November 7, 2026, in 'Free Press Gujarat' and 'Lokmitra' as mandated under Regulation 47 of SEBI Listing Regulations. No specific financial performance figures were legible or detailed in the provided announcement extract. This filing represents a purely procedural regulatory compliance requirement.

• Newspaper publication of Q2 financial results for the period ended September 30, 2026
• Advertisements published on November 7, 2026
• Published in two newspapers: Free Press Gujarat and Lokmitra
• Compliance submission under Regulation 47 of SEBI LODR Regulations

Crestchem Ltd reported its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Consolidated profit for the half-year stood at ₹141.20 Lakhs (₹1.41 Cr) compared to ₹375.75 Lakhs for the full year ended March 31, 2026. Subsidiary Oleo Biosciences Private Limited contributed zero revenue and a net loss of ₹8.01 Lakhs for the quarter. Total assets stood at ₹1,512.42 Lakhs as of September 30, 2026, with property, plant, and equipment rising to ₹80.92 Lakhs from ₹19.44 Lakhs in March 2026.

• H1 FY27 consolidated profit after tax reported at ₹141.20 Lakhs
• Net cash generated from operating activities for H1 FY27 was ₹7.57 Lakhs
• Subsidiary Oleo Biosciences reported Nil revenue and a net loss of ₹8.01 Lakhs for Q2
• Property, plant, and equipment increased to ₹80.92 Lakhs from ₹19.44 Lakhs as of March 31, 2026
• Long-term borrowings stood at ₹35.00 Lakhs as of September 30, 2026, up from Nil in March 2026

Crestchem Ltd held a board meeting on August 12, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The meeting was notably brief, concluding in just 15 minutes. While the specific P&L figures were not detailed in the cover letter, the company enters this period with a TTM revenue of Rs 30 Cr and a high ROCE of 43.4%. Investors should monitor the full results for growth relative to the March 2026 quarter's revenue of Rs 10.23 Cr.

• Board meeting conducted and concluded within 15 minutes (4:30 PM to 4:45 PM) on August 12, 2026.
• Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
• Company maintains a debt-free balance sheet (D/E of 0.00) as per latest financial context.
• TTM PAT stands at Rs 3 Cr with an operating profit margin of 10.7% leading into this result.
• Promoter holding remains relatively low at 29.76% as of June 2026.

Crestchem Ltd has scheduled a board meeting on August 12, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The board will also formally note a fine imposed by the BSE for the late submission of its consolidated cash flow statement. This delay was reportedly due to the registration of a new subsidiary on March 31, 2026. Investors should monitor if the company can sustain the revenue momentum seen in Q4 FY26, where it reported sales of ₹10.23 crore.

• Board meeting scheduled for August 12, 2026, at 04:30 PM to approve Q1 FY27 results.
• Company to address a BSE fine regarding late submission of consolidated cash flow statements.
• The reporting delay was linked to a new subsidiary registered on March 31, 2026.
• Latest TTM revenue stands at ₹30 crore with a PAT of ₹3 crore.
• Promoter holding remains relatively low at 29.76% as of June 2026.

BSE Limited has notified Crestchem Ltd of an outstanding fine amounting to ₹1,06,200 for the late submission of its Consolidated Cash Flow Statement under Regulation 33. The company clarified that its subsidiary, Oleo Biosciences Private Limited, was incorporated on the very last day of the financial year (March 31, 2026) and had no financial transactions to report. Crestchem is actively seeking a waiver for this fine, arguing that there was no financial data requiring inclusion at that time. Given the company's TTM PAT of ₹3 crore, the fine is immaterial to its overall financial health.

• BSE notified the company of a ₹1,06,200 fine via email on August 4, 2026.
• The fine pertains to the late submission of the Consolidated Cash Flow Statement for FY26.
• Subsidiary Oleo Biosciences Private Limited was incorporated on March 31, 2026, with zero transactions.
• The fine amount represents approximately 0.35% of the company's TTM PAT of ₹3 crore.
• The company is positive about receiving a waiver and expects no material financial impact.

Crestchem Ltd has filed a clarification with the BSE stating that the Escrow Payment Mechanism is not applicable to the company. The filing confirms the absence of several specific account types, including No Lien escrow, Interest Payment, Sinking Fund, and General accounts. This is a procedural regulatory disclosure and does not indicate any change in the company's financial position or operations. Investors should view this as a routine compliance update.

• Confirmed 0 No Lien escrow accounts are maintained by the company
• Confirmed 0 Interest Payment Accounts or Sinking Fund Accounts exist
• Official disclosure submitted to BSE on July 15, 2026
• Statement signed by Nitinkumar S. Shah, Company Secretary and Compliance Officer